Individualized antithrombotic therapy in high-risk cardiovascular patients

Area of Science:

• Cardiology
• Interventional Cardiology
• Pharmacology

Background:

• Current guidelines recommend 6-12 months of dual antiplatelet therapy (DAPT) after drug-eluting stent (DES) implantation.
• Thrombo-ischemic events and bleeding complications can occur beyond one year post-stent implantation.
• Identifying high-risk patients who may benefit from prolonged DAPT is crucial.

Purpose of the Study:

• To review recent randomized clinical trials and meta-analyses on prolonged DAPT (>12 months) after percutaneous coronary intervention.
• To evaluate the efficacy and safety of extended DAPT in reducing thrombo-ischemic events.
• To determine specific patient populations that may benefit from prolonged DAPT.

Main Methods:

• Review of randomized clinical studies including DAPT, ITALIC, OPTIDUAL, and PEGASUS.
• Analysis of meta-analyses investigating prolonged DAPT.
• Assessment of outcomes related to thrombo-ischemic events and bleeding.

Main Results:

• Data from recent trials and meta-analyses suggest potential benefits of prolonged DAPT in select high-risk patients.
• The risk-benefit balance of extended DAPT varies among different patient subgroups.
• Specific criteria for identifying patients who benefit from DAPT beyond 12 months are discussed.

Conclusions:

• Prolonged DAPT may be beneficial for specific high-risk patient cohorts after DES implantation.
• Careful patient selection is essential to optimize outcomes and minimize bleeding risks.
• Further research may refine guidelines for extended DAPT duration based on individual patient risk profiles.